225 related articles for article (PubMed ID: 36816572)
1. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.
Boyle T; Fernando SL; Drummond J; Fontes A; Parratt J
Front Neurol; 2023; 14():1092373. PubMed ID: 36816572
[TBL] [Abstract][Full Text] [Related]
2. Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Frederick MC; Cameron MH
Curr Neurol Neurosci Rep; 2016 Mar; 16(3):26. PubMed ID: 26847090
[TBL] [Abstract][Full Text] [Related]
3. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
[TBL] [Abstract][Full Text] [Related]
5. Balo's concentric sclerosis: An atypical demyelinating disease in pediatrics.
Arenas Vargas LE; Bedoya Morales AM; Rincón Carreño C; Espitia Segura OM; Penagos N
Mult Scler Relat Disord; 2020 Sep; 44():102198. PubMed ID: 32531753
[TBL] [Abstract][Full Text] [Related]
6. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
[TBL] [Abstract][Full Text] [Related]
7. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.
Vakrakou AG; Tzanetakos D; Evangelopoulos ME; Argyrakos T; Tzartos JS; Anagnostouli M; Andreadou E; Koutsis G; Velonakis G; Toulas P; Gialafos E; Dimitrakopoulos A; Psimenou E; Stefanis L; Kilidireas C
Ther Adv Neurol Disord; 2021; 14():17562864211006503. PubMed ID: 34046086
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Plasma Exchange for Treatment-Resistant Tumefactive Demyelinating Lesion: A Case Report.
Vilayet S; Hayes E; Barakat M; Budisavljevic M; Achanti A
Cureus; 2024 Feb; 16(2):e53786. PubMed ID: 38465038
[TBL] [Abstract][Full Text] [Related]
9. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
10. Tumefactive demyelinating lesions.
Dagher AP; Smirniotopoulos J
Neuroradiology; 1996 Aug; 38(6):560-5. PubMed ID: 8880719
[TBL] [Abstract][Full Text] [Related]
11. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
[TBL] [Abstract][Full Text] [Related]
12. Atypical inflammatory demyelinating syndromes of the CNS.
Hardy TA; Reddel SW; Barnett MH; Palace J; Lucchinetti CF; Weinshenker BG
Lancet Neurol; 2016 Aug; 15(9):967-981. PubMed ID: 27478954
[TBL] [Abstract][Full Text] [Related]
13. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
[TBL] [Abstract][Full Text] [Related]
14. Balo's concentric lesions with concurrent features of Schilder's disease in relapsing multiple sclerosis: neuropathological findings.
Kurdi M; Ramsay D
Autops Case Rep; 2016; 6(4):21-26. PubMed ID: 28210570
[TBL] [Abstract][Full Text] [Related]
15. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
Balloy G; Pelletier J; Suchet L; Lebrun C; Cohen M; Vermersch P; Zephir H; Duhin E; Gout O; Deschamps R; Le Page E; Edan G; Labauge P; Carra-Dallieres C; Rumbach L; Berger E; Lejeune P; Devos P; N'Kendjuo JB; Coustans M; Auffray-Calvier E; Daumas-Duport B; Michel L; Lefrere F; Laplaud DA; Brosset C; Derkinderen P; de Seze J; Wiertlewski S;
J Neurol; 2018 Oct; 265(10):2251-2259. PubMed ID: 30054790
[TBL] [Abstract][Full Text] [Related]
16. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
[TBL] [Abstract][Full Text] [Related]
17. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
18. Atypical inflammatory demyelinating lesions and atypical multiple sclerosis.
Ayrignac X; Carra-Dallière C; Labauge P
Rev Neurol (Paris); 2018 Jun; 174(6):408-418. PubMed ID: 29673573
[TBL] [Abstract][Full Text] [Related]
19. Newly Diagnosed Tumefactive Demyelinating Lesion and Multiple Sclerosis After COVID-19 Infection.
Erdoğan T; Koçer B; Şen S; Balcı BP; Terzi M
Noro Psikiyatr Ars; 2023; 60(3):223-230. PubMed ID: 37645083
[TBL] [Abstract][Full Text] [Related]
20. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
